Abstract A32: GIGA-564, a Third Generation Anti-Ctla-4 with Minimal Ability to Block CTLA-4 Binding to B7 Ligands, Has Enhanced Efficacy but Reduced Toxicity Compared to Ipilimumab in Pre-Clinical Models
Cancer Immunology Research(2022)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined